News Room
News Room
News Room
Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development
– New AI model, co-developed by Evozyne and NVIDIA, can create novel therapeutic proteins for a new era of drug development – CHICAGO—January 12, [...]
Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
– Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placebo – CHICAGO—January 11, 2023 – A [...]
Veteran Technology Executive Mike Gamson Named Evozyne CEO
– Gamson to set commercial direction, strengthen foundation for growth – CHICAGO, January 9, 2023 – Evozyne, a fast-growing biology engineering company, today [...]
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
– Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors – CHICAGO—November 3, 2022 – Emalex Biosciences announced [...]
Outstanding First Half for Paragon and its Portfolio Companies
Paragon and its portfolio companies continue to successfully advance biology-based innovation, creating impressive results. First Half 2022 Newsletter We are a [...]
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa and [...]
